[Featured Stock] Boryung Pharmaceutical's Aplecidin Shows COVID-19 Treatment Effect... 74% Discharge Rate After Administration 'Strong'

[Asia Economy Reporter Hyunseok Yoo] Boryung Pharmaceutical is showing strength. It appears that the news of the multiple myeloma treatment 'Aplidin,' for which it has an exclusive sales contract with the Spanish pharmaceutical company PharmaMar, having a COVID-19 treatment effect has influenced this trend.

As of 2:45 PM on the 27th, Boryung Pharmaceutical was trading at 23,050 KRW, up 1.54% (350 KRW) compared to the previous trading day.

PharmaMar announced on the 26th (local time) that it administered Aplidin to 45 patients infected with the novel coronavirus (COVID-19). They reported that 74% of the patients were discharged within 7 days. Among the clinical trial subjects, 86.7% were patients with moderate to severe symptoms.

The study, titled 'APLICOV-PC,' was published on MedRxiv, a preprint server for medical research. However, it is known that this study has not undergone the 'peer review' process. Peer review refers to the evaluation of research by colleagues other than the study participants to identify flaws or areas for improvement.

Meanwhile, Boryung Pharmaceutical, which holds the exclusive sales rights in Korea, previously stated that Aplidin showed antiviral effects at lower concentrations compared to Remdesivir in animal experiments. Generally, lower drug concentrations correspond to fewer side effects.

Boryung Pharmaceutical announced that Aplidin exhibited 2,400 to 2,800 times the antiviral activity of Remdesivir, which has been approved for special import as a COVID-19 treatment, in monkey kidney cell experiments.

This content was produced with the assistance of AI translation services.